盐酸羟考酮缓释片弱化二阶梯治疗的疗效和安全性研究  

Efficacy and Safety of Oxycodone Hydrochloride Sustained-release Tablets with De-escalation Application

作　　者：王启盛[1] 吕亚莉[2] 徐辉 陈传军[2] 刘笑笑[2] 杨彬[2] 

机构地区：[1]浙江新昌县人民医院药剂科,浙江绍兴312500 [2]浙江新昌县人民医院肿瘤内科,浙江绍兴312500 [3]枣庄市立四院医务科,山东枣庄277500

出　　处：《中国药房》2014年第42期3985-3987,共3页China Pharmacy

基　　金：浙江省医学会临床科研基金项目(No.2012ZYC-B3)

摘　　要：目的:探讨中度癌痛起始药物应用盐酸羟考酮与常规二阶梯治疗的疗效及不良反应发生情况。方法:前瞻性研究2012年3月-2014年3月中度癌痛患者260例,通过随机数字表法分为A组与B组。A组136例,起始应用盐酸羟考酮缓释片10 mg/12h口服;B组124例,按照常规二阶梯应用曲马多缓释片100 mg/12h口服。服用盐酸羟考酮缓释片或盐酸曲马多缓释片后1h进行疼痛评估,按照美国国家综合癌症网络(NCCN)成人癌痛指南(中国2010版)原则进行滴定。观察两组患者的镇痛效果和不良反应。结果:A组与B组的镇痛总有效率分别为89.7%、83.1%(P<0.01),ADR发生率分别为66.2%、58.9%(P>0.05)。结论:盐酸羟考酮缓释片弱化二阶梯治疗癌痛疗效显著,能够及时有效地控制疼痛,与对照组比较不良反应无差异,使用安全,有利于癌痛患者生活质量的提高。OBJECTIVE： To discuss therapeutic efficacy and ADR of oxycodone hydrochloride and conventional two-step treatment for moderate cancer pain. METHODS： In prospective study, 260 patients with moderate cancer pain during Mar. 2012 to Mar. 2014 were randomly divided into group A and group B. 136 cases in group A were given Oxycodone hydrochloride sustained-release tablets orally 100 mg/12 h initially; 124 cases in group B were given Tramadol sustained-release tablets orally 100 mg/12 h according to the conventional two-step treatment. The pain assessment was performed 1 h after taking Oxycodone hydrochloride sustained-release tablets or Tramadol sustained-release tablets; titration was carried out according to NCCN guidance of adult＇ s cancer pain （China 2010 edition）. Analgesic effect and ADR were observed in 2 groups. RESULTS： The total effective rates of analgesia in group A and B were 89.7% and 83.1% （P〈0.01）, and the incidence of ADR were 66.2% and 58.9% （P〉 0.05）. CONCLUSIONS： Oxycodone hydrochloride sustained-release tablets with de-escalation application has obvious curative effect, can effectively control pain, and has no difference in ADR compared with the control group; it is safe and conducive to the quality of life in cancer patients.

关 键 词：盐酸羟考酮缓释片 中度癌痛 弱化二阶梯 疗效 安全性 

分 类 号：R971.1[医药卫生—药品] R969.4[医药卫生—药学]